Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed Phase 4 Interventional Results available

Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

NCT01097395
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
ribavirin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

NCT03183245
View directory record Official record
Conditions
Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
Interventions
Human Acellular Vessel (HAV), Arteriovenous fistula (AVF), Hemodialysis
Biological · Procedure · Other
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 22, 2026, 10:50 PM EDT
Withdrawn Phase 2 Interventional

Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C

NCT00930995
View directory record Official record
Conditions
Hepatitis C
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Roseville, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 22, 2026, 10:50 PM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 22, 2026, 10:50 PM EDT
Terminated Phase 4 Interventional

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

NCT00274495
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Fatty Liver
Interventions
Rosiglitazone and Pegasys/Ribavirin
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

NCT02480712
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 2 Interventional Results available

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

NCT04544956
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 22, 2026, 10:50 PM EDT
Recruiting Not applicable Interventional

Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH

NCT03845205
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Hepatitis
Interventions
Integrated AUD Treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 10:50 PM EDT
Completed No phase listed Observational

Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression

NCT00205075
View directory record Official record
Conditions
Hepatic Fibrogenesis, Hepatitis C
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access

NCT02360007
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Interim Buprenorphine Treatment (IBT)
Drug
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

NCT02055365
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 22, 2026, 10:50 PM EDT
Terminated Phase 2 Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

NCT00228592
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepeX-B, Hepatitis B Immune Globulin (HBIg)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 22, 2026, 10:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

NCT07298330
View directory record Official record
Conditions
Chronic Hepatitis D Infection
Interventions
Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Davis, California • Sacramento, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270
View directory record Official record
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 22, 2026, 10:50 PM EDT
Completed No phase listed Observational

Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

NCT01771653
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 22, 2026, 10:50 PM EDT
Enrolling by invitation No phase listed Observational

Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation

NCT04234139
View directory record Official record
Conditions
Liver Diseases, Alcoholic, Alcohol-Related Disorders, Transplant; Failure, Liver, Transplant; Complication, Rejection, Liver Diseases, Hepatitis, Alcoholic, Alcohol-Induced Disorders
Interventions
liver transplant
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 2 Interventional

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

NCT01058512
View directory record Official record
Conditions
Hepatitis C
Interventions
NOV-205
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers

NCT02404805
View directory record Official record
Conditions
HIV, Hepatitis C
Interventions
dolutegravir, simeprevir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Not applicable Interventional

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

NCT00000896
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
San Diego, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 10:50 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose

NCT06855836
View directory record Official record
Conditions
Overdose
Interventions
MI-CHANCE (TS + FTIR + MI), TS + FTIR + Flu and Hepatitis A Education
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

NCT04535544
View directory record Official record
Conditions
Hepatitis D, Chronic
Interventions
JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Redwood City, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

NCT00048945
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
PEGASYS
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
15
States / cities
Scottsdale, Arizona • Downey, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Not applicable Interventional Results available

Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV

NCT03652675
View directory record Official record
Conditions
Alcohol Use Disorder, HIV/AIDS, Hepatitis C, Binge Drinking
Interventions
Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 22, 2026, 10:50 PM EDT
Completed Not applicable Interventional Results available

Effect of Chair Yoga on Elders With Osteoarthritis

NCT02113410
View directory record Official record
Conditions
Osteoarthritis (OA)
Interventions
Sit 'N' Fit Chair Yoga (SNFCY), Health Education Program (HEP)
Behavioral
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Deerfield Beach, Florida • Pembroke Pines, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 22, 2026, 10:50 PM EDT